Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

Inclusion Criteria for registration : (with labs performed within 21 days of initiation of protocol therapy): * Patients diagnosed with multiple myeloma based on International Myeloma Foundation 2003 Diagnostic Criteria. * Patients must have symptomatic myeloma with myeloma-related organ damage. * Patients must have myeloma that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chains. * Age between 18 and 65 years at the time of signing the informed consent document. * ECOG performance status \<2 (Karnofsky ≥ 60%) * Negative HIV blood test Exclusion Criteria for registration (section 4.2): * Participants must not have been treated with any prior systemic therapy for multiple myeloma. Treatment by localized radiotherapy is not an exclusion criterion if an interval of at least two weeks between the end of radiotherapy and initiation of protocol therapy entry in the study is observed. Similarly, the dose of corticosteroids received by the participant should not exceed the equivalent of 160 mg of dexamethasone over a two-week period before initiation of protocol therapy. * Primary amyloidosis (AL) or myeloma complicated by amylosis. * Participants may not be receiving any other study investigational agents. * Participants with known brain metastases * Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to study agents * Platelet count \< 50,000/mm3 pe…